ArQule, Inc. to Report First Quarter Financial Results on April 19, 2001

Apr 12, 2001, 01:00 ET from ArQule, Inc. 

    WOBURN, Mass., April 12 /PRNewswire/ -- ArQule, Inc. (Nasdaq:   ARQL) today
 announced that the Company will report its financial results for the First
 Quarter 2001 on Thursday, April 19, 2001 at 7:00 a.m. Eastern, and hold a
 conference call at 9:00 a.m. Eastern.  Dr. Stephen A. Hill, CEO and President,
 and David C. Hastings, Chief Financial Officer, will lead the call.
 
     Date:                                Thursday, April 19, 2001
     Time:                                9:00 a.m. Eastern
     Conference Call Numbers:
     Toll Free:                           (800) 406-5345
     Toll:                                (913) 981-5571
     Access Code:                         705278
     Webcast:                             www.arqule.com
 
     A replay of the conference call will be available for 5 days, which can be
 accessed by dialing toll-free (888) 203-1112, and outside the U.S.
 (719) 457-0820.  The access code is 705278.
     ArQule collaborates with leading pharmaceutical and biotechnology
 companies to synthesize and optimize small molecules that have the potential
 to enter clinical development and become medicines.
     ArQule's Parallel Track(TM) Drug Discovery program integrates key
 technologies for high-throughput, automated synthesis of small molecules with
 technologies that enable more informed, intelligent decisions about what
 molecules to synthesize. Parallel use of these "what to make" and "how to
 make" technologies results in rapid, iterative cycles of lead generation,
 qualification, and optimization of clinical drug candidates.  In addition,
 ArQule also offers access to their high-throughput, automated synthesis and
 lead optimization platforms through technology licensing agreements.  ArQule
 is based in Woburn and Medford, Massachusetts.  For additional information,
 please visit www.arqule.com.
     Camitro, a wholly owned subsidiary of ArQule, is dedicated to the
 development and application of innovative computational technologies for the
 design, selection and optimization of novel drug candidates. Camitro's
 predictive models enable scientists to assess ADMET properties of chemical
 compounds throughout the discovery process, from the earliest stages of
 compound selection and library design through lead candidate evaluation and
 re-design.  Its integrated platform of models permits the optimization of
 multiple ADMET properties simultaneously, at high throughput, based upon
 chemical structure alone.  Camitro is headquartered in Menlo Park, California
 with a wholly owned subsidiary, Camitro UK, Ltd., located in Cambridge, UK.
 For additional information, please visit www.camitro.com.
 
      ArQule Contact:
      David C. Hastings
      Chief Financial Officer
      (781) 994-0300
      www.arqule.com
 
      Media Contacts:
      Sharon Karlsberg
      Vivienne Blake
      Feinstein Kean Healthcare
      (617) 577-8110
 
 

SOURCE  ArQule, Inc.


    WOBURN, Mass., April 12 /PRNewswire/ -- ArQule, Inc. (Nasdaq:   ARQL) today
 announced that the Company will report its financial results for the First
 Quarter 2001 on Thursday, April 19, 2001 at 7:00 a.m. Eastern, and hold a
 conference call at 9:00 a.m. Eastern.  Dr. Stephen A. Hill, CEO and President,
 and David C. Hastings, Chief Financial Officer, will lead the call.
 
     Date:                                Thursday, April 19, 2001
     Time:                                9:00 a.m. Eastern
     Conference Call Numbers:
     Toll Free:                           (800) 406-5345
     Toll:                                (913) 981-5571
     Access Code:                         705278
     Webcast:                             www.arqule.com
 
     A replay of the conference call will be available for 5 days, which can be
 accessed by dialing toll-free (888) 203-1112, and outside the U.S.
 (719) 457-0820.  The access code is 705278.
     ArQule collaborates with leading pharmaceutical and biotechnology
 companies to synthesize and optimize small molecules that have the potential
 to enter clinical development and become medicines.
     ArQule's Parallel Track(TM) Drug Discovery program integrates key
 technologies for high-throughput, automated synthesis of small molecules with
 technologies that enable more informed, intelligent decisions about what
 molecules to synthesize. Parallel use of these "what to make" and "how to
 make" technologies results in rapid, iterative cycles of lead generation,
 qualification, and optimization of clinical drug candidates.  In addition,
 ArQule also offers access to their high-throughput, automated synthesis and
 lead optimization platforms through technology licensing agreements.  ArQule
 is based in Woburn and Medford, Massachusetts.  For additional information,
 please visit www.arqule.com.
     Camitro, a wholly owned subsidiary of ArQule, is dedicated to the
 development and application of innovative computational technologies for the
 design, selection and optimization of novel drug candidates. Camitro's
 predictive models enable scientists to assess ADMET properties of chemical
 compounds throughout the discovery process, from the earliest stages of
 compound selection and library design through lead candidate evaluation and
 re-design.  Its integrated platform of models permits the optimization of
 multiple ADMET properties simultaneously, at high throughput, based upon
 chemical structure alone.  Camitro is headquartered in Menlo Park, California
 with a wholly owned subsidiary, Camitro UK, Ltd., located in Cambridge, UK.
 For additional information, please visit www.camitro.com.
 
      ArQule Contact:
      David C. Hastings
      Chief Financial Officer
      (781) 994-0300
      www.arqule.com
 
      Media Contacts:
      Sharon Karlsberg
      Vivienne Blake
      Feinstein Kean Healthcare
      (617) 577-8110
 
 SOURCE  ArQule, Inc.